Business Wire

The SIGMA Group Chooses ExaGrid to Back Up Customer Data

25.6.2020 16:10:00 EEST | Business Wire | Press release

Share

ExaGrid ® today announced that INFIDIS, a global IT integrator and solutions provider, led The SIGMA Group to choose ExaGrid’s tiered backup storage solution to enhance data protection and optimize its backups and data restoration capabilities, needed to offer its customers backup as a service.

The SIGMA Group is a digital services company based in France, specialized in software publishing, integration of tailor-made digital solutions, and outsourcing of information systems and cloud solutions. The SIGMA Group now uses ExaGrid to store customer backups, as well as its own backed up data, in addition to using ExaGrid to replicate data from its primary site to its disaster recovery (DR) site. Adding ExaGrid to The SIGMA Group’s backup environment has allowed the company to keep up with customer data growth and deliver on its SLAs.

“To meet Sigma's expectations, INFIDIS proposed the ExaGrid solution because of the many benefits it offers such as performance that is guaranteed over time, predictable costs, a scalable architecture which allows for progressive and granular investments as needed, very fast tape copy, and easily maintained long-term retention,” said Frédéric Floret, IT Business Engineer at INFIDIS.

“Using ExaGrid allows us to provide high-quality backup services to our customers,” said Mickaël Collet, cloud architect at The SIGMA Group. “We guarantee high SLAs especially on backup services and ExaGrid helps us to deliver on those. Our backup services include performance commitments on restorations and ExaGrid’s Landing Zone allows us to keep the freshest data in a non-deduplicated format to guarantee optimal restoration performance.”

The SIGMA Group is responsible for backing up 650TB of customer data, which is backed up in daily incrementals, as well as weekly and monthly fulls. The SIGMA Group’s IT staff have found that ExaGrid’s unique scale-out architecture has been helpful in keeping up with growing data. “We need to adjust capacity as closely as possible to customer needs and not have to oversize backup infrastructures based on growth forecasts,” said Alexandre Chaillou, infrastructure manager at The SIGMA Group. “We started with two ExaGrid systems, with one appliance at our primary data center and one at our remote data center. We expanded our two ExaGrid systems, which now are made up of 14 ExaGrid appliances. ExaGrid’s scale-out approach allows us to add capacity while making it possible to only add what is needed.”

ExaGrid writes backups directly to a disk-cache Landing Zone, avoiding inline processing and ensuring the highest possible backup performance, which results in the shortest backup window. Adaptive Deduplication performs deduplication and replication in parallel with backups while providing full system resources to the backups for the shortest backup window.

All of ExaGrid’s appliances contain not just disk but also processing power, memory, and bandwidth. When the system needs to expand, additional appliances are simply attached to the existing system. This type of configuration allows the system to maintain all the aspects of performance as the amount of data grows, allowing organizations to pay for what they need when they need it. Appliances of any size or age can be mixed and matched in a single system with capacities of up to a 2PB full backup plus retention and an ingest rate of up to 432TB per hour. Once virtualized, they appear as a single system to the backup server, and load balancing of all data across servers is automatic.

Read the complete Success Story to learn more about The SIGMA Group’s experience using ExaGrid. ExaGrid’s published customer success stories and enterprise stories demonstrate how satisfied customers are with ExaGrid’s unique architectural approach, differentiated product, and unrivaled customer support.

About INFIDIS

INFIDIS is a 20-year-old global IT integrator and solutions provider that is in line with industry leaders. Its solution architects and engineers design, build, deliver and manage IT solutions and services for customers of all sizes and from a wide variety of industries.

INFIDIS help customers to adapt their infrastructures to the requirements of their businesses by offering them high-performance and secure solutions for the optimization of data centers in heterogeneous environments. INFIDIS offers an end-to-end support, independent of constructors and editors and based on a large ecosystem of skills, supplying all the necessary bricks to the building of the base of the new generation of infrastructures.

About ExaGrid

ExaGrid provides tiered backup storage with a unique disk-cache Landing Zone, long-term retention repository, and scale-out architecture. ExaGrid’s Landing Zone provides for the fastest backups, restores, and instant VM recoveries. The retention repository offers the lowest cost for long-term retention. ExaGrid’s scale-out architecture includes full appliances and ensures a fixed-length backup window as data grows, eliminating expensive forklift upgrades and product obsolescence. Visit us at exagrid.com or connect with us on LinkedIn. See what our customers have to say about their own ExaGrid experiences and why they now spend significantly less time on backup in our customer success stories.

ExaGrid is a registered trademark of ExaGrid Systems, Inc. All other trademarks are the property of their respective holders.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Stacey Foster
ExaGrid
sfoster@exagrid.com
508-898-2872 x248

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release

For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro

Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release

Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye